4 research outputs found
Selective, Nontoxic CB<sub>2</sub> Cannabinoid <i>o</i>‑Quinone with in Vivo Activity against Triple-Negative Breast Cancer
Triple-negative breast
cancer (TNBC) represents a subtype of breast
cancer characterized by high aggressiveness. There is no current targeted
therapy for these patients whose prognosis, as a group, is very poor.
Here, we report the synthesis and evaluation of a potent antitumor
agent in vivo for this type of breast cancer designed as a combination
of quinone/cannabinoid pharmacophores. This new compound (<b>10</b>) has been selected from a series of chromenopyrazolediones with
full selectivity for the nonpsychotropic CB<sub>2</sub> cannabinoid
receptor and with efficacy in inducing death of human TNBC cell lines.
The dual concept quinone/cannabinoid was supported by the fact that
compound <b>10</b> exerts antitumor effect by inducing cell
apoptosis through activation of CB<sub>2</sub> receptors and through
oxidative stress. Notably, it did not show either cytotoxicity on
noncancerous human mammary epithelial cells nor toxic effects in vivo,
suggesting that it may be a new therapeutic tool for the management
of TNBC
Selective, Nontoxic CB<sub>2</sub> Cannabinoid <i>o</i>‑Quinone with in Vivo Activity against Triple-Negative Breast Cancer
Triple-negative breast
cancer (TNBC) represents a subtype of breast
cancer characterized by high aggressiveness. There is no current targeted
therapy for these patients whose prognosis, as a group, is very poor.
Here, we report the synthesis and evaluation of a potent antitumor
agent in vivo for this type of breast cancer designed as a combination
of quinone/cannabinoid pharmacophores. This new compound (<b>10</b>) has been selected from a series of chromenopyrazolediones with
full selectivity for the nonpsychotropic CB<sub>2</sub> cannabinoid
receptor and with efficacy in inducing death of human TNBC cell lines.
The dual concept quinone/cannabinoid was supported by the fact that
compound <b>10</b> exerts antitumor effect by inducing cell
apoptosis through activation of CB<sub>2</sub> receptors and through
oxidative stress. Notably, it did not show either cytotoxicity on
noncancerous human mammary epithelial cells nor toxic effects in vivo,
suggesting that it may be a new therapeutic tool for the management
of TNBC
Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship
GPR55 is an orphan G-protein coupled receptor involved
in various
pathophysiological conditions. However, there are only a few noncannabinoid
GPR55 ligands reported so far. The lack of potent and selective GPR55
ligands precludes a deep exploration of this receptor. The studies
presented here focused on a thienopyrimidine scaffold based on the
GPR55 antagonist ML192, previously discovered by high-throughput screening.
The GPR55 activities of the new synthesized compounds were assessed
using β-arrestin recruitment assays in Chinese hamster ovary
cells overexpressing human GPR55. Some derivatives were identified
as GPR55 antagonists with functional efficacy and selectivity versus
CB1 and CB2 cannabinoid receptors
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis
A combination
of molecular modeling and structure–activity
relationship studies has been used to fine-tune CB<sub>2</sub> selectivity
in the chromenopyrazole ring, a versatile CB<sub>1</sub>/CB<sub>2</sub> cannabinoid scaffold. Thus, a series of 36 new derivatives covering
a wide range of structural diversity has been synthesized, and docking
studies have been performed for some of them. Biological evaluation
of the new compounds includes, among others, cannabinoid binding assays,
functional studies, and surface plasmon resonance measurements. The
most promising compound [<b>43</b> (PM226)], a selective and
potent CB<sub>2</sub> agonist isoxazole derivative, was tested in
the acute phase of Theiler’s murine encephalomyelitis virus-induced
demyelinating disease (TMEV-IDD), a well-established animal model
of primary progressive multiple sclerosis. Compound <b>43</b> dampened neuroinflammation by reducing microglial activation in
the TMEV